Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

APVO210

Other · developed by Aptevo Therapeutics

Phase 1 Most advanced trial (none active)
APVO Developer
1 Registered trials

What is APVO210?

APVO210 is a drug studied in psoriasis and ulcerative colitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Dermatology, Gastroenterology
Developer
Aptevo Therapeutics (APVO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03768219 Phase 1 Psoriasis Terminated APVO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

PsoriasisUlcerative Colitis

More from Aptevo Therapeutics

ALG.APV-527 Phase 1/2 ES414 Phase 1 Mipletamig Phase 1 Otlertuzumab Phase 1/2

Follow APVO, the company behind APVO210

See APVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

APVO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.